Hyderabad-based Dr Reddy’s Laboratories has launched the prescription drug Minoxidil topical resolution USP 2 per cent and 5 per cent for the therapy of feminine sample hair loss (FPHL). Dr Reddy’s will promote its merchandise beneath the model names Mintop 2 per cent and Mintop Eva 5 per cent respectively.
The launch follows the first-ever approval of the extra indication by the Central Medicine Normal Management Group (CDSCO) in India for using Minoxidil topical resolution USP 2 per cent and 5 per cent for therapy of FPHL.
Minoxidil topical resolution will turn out to be accessible as a first-line therapy possibility for FPHL in India. Whereas Minoxidil topical resolution has been accredited in India for the therapy of alopecia in males (male sample baldness), there are presently no different medication accredited for the therapy of FPHL in India.
MV Ramana, CEO, Branded Markets (India & Rising Markets) Dr Reddy’s Laboratories stated, “This approval marks the first-ever given to a first-line therapy possibility for feminine sample hair loss, and really fulfils a hitherto unmet want. Our Minoxidil topical resolution (Mintop 2 per cent and Mintop Eva 5 per cent) for ladies might be extensively accessible within the nation, and thru this launch, we hope to deliver aid and luxury to sufferers identified with FPHL in India.”